🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. Matched placebo for test product, Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Chronic rhinosinusitis with nasal polyps

    phase 3 small molecule active

    1 trial

  2. Matched placebo for test product, Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Chronic rhinosinusitis with nasal polyps

    phase 3 small molecule active

    1 trial

  3. Matches test film-coated tablets, Wakix 4.5 mg film-coated tablets, Wakix 18 mg film-coated tablets

    Bioprojet Pharma

    Narcolepsy

    phase 3 small molecule active

    1 trial

  4. Matching Placebo

    IRONWOOD PHARMACEUTICALS INC

    Chronic Constipation

    phase 3 small molecule completed

    1 trial

  5. Matching Placebo for Piclidenoson, Piclidenoson

    Can-Fite BioPharma

    Plaque psoriasis

    phase 3 small molecule active

    1 trial

  6. Matching Placebo for TAK-279 Dose A, ZASOCITINIB, Matching Placebo for TAK-279 Dose B, ZASOCITINIB

    Takeda

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  7. Matching Placebo for TAK-279 Dose B, ZASOCITINIB, ZASOCITINIB, Matching Placebo for TAK-279 Dose A

    Takeda

    Active Psoriatic Arthritis Stratified by Prior Biologic Use

    phase 3 small molecule active

    1 trial

  8. Matching Placebo for TAK-279, ZASOCITINIB

    Takeda

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  9. Matching Placebo for Upadacitinib

    AbbVie

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  10. Matching placebo MGL-3196 60 mg film-coated tablet, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 100 mg film-coated tablet., MGL-3196 60 mg oral, MGL-3196 100 mg oral, MGL-3196 80 mg oral

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  11. Matching placebo for BAY 597939 2.5 mg filmcoated tablets, Rivaroxaban 2.5 mg

    The George Institute

    Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.

    phase 3 small molecule active

    1 trial

  12. Matching placebo for Tezepelumab solution for injection, TEZEPELUMAB

    AstraZeneca AB

    Severe Uncontrolled Asthma Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that asthma attacks are still occurring despite the use of other available treatments

    phase 3 small molecule active

    1 trial

  13. Matching placebo tablet, JNJ-67953964

    Janssen-Cilag International N.V.

    Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia

    phase 3 small molecule active

    1 trial

  14. Matching placebo tablet, JNJ-67953964

    Janssen-Cilag International N.V.

    Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia

    phase 3 small molecule active

    1 trial

  15. Mavorixafor, Mavorixafor Placebo Capsules

    X4 Pharmaceuticals, Inc

    Neutropenias

    phase 3 small molecule active

    1 trial

  16. Mavorixafor, Placebo to Test IMP

    X4 Pharmaceuticals, Inc

    WHIM Syndrome

    phase 3 small molecule active

    1 trial

  17. Medical Air, KALINOX 50%/50%, gaz médicinal comprimé

    Tour Hekla

    Resistant Depression in the Elderly Subject

    phase 3 small molecule active

    1 trial

  18. Medpulser Electroporation with Bleomycin

    INOVIO PHARMACEUTICALS, INC.

    Head Neck Cancer

    phase 3 other terminated

    1 trial

  19. Medtronic Talent Stent-Graft-System

    Rhythm Pharmaceuticals Netherlands B.V.

    Aortic Diseases

    phase 3 other completed

    1 trial

  20. Melflufen

    Oncopeptides AB (publ)

    Multiple Myeloma

    phase 3 small molecule terminated

    1 trial

  21. Metalyse 5 000 units (25 mg) powder for solution for injection

    Boehringer Ingelheim

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  22. Metalyse 5 000 units (25 mg) powder for solution for injection

    Pari Pharma GmbH

    Adult patients with a LVOS with large core within 9 hours of symptoms onset or last seen well, or with a diffusion weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch in case of unknown onset.

    phase 3 small molecule active

    1 trial

  23. Metformin

    United Therapeutics Europe Ltd

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule active

    1 trial

  24. Metformin

    AstraZeneca

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources